scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1046722588 |
P356 | DOI | 10.1186/1475-2875-13-189 |
P932 | PMC publication ID | 4045961 |
P698 | PubMed publication ID | 24886347 |
P5875 | ResearchGate publication ID | 262789114 |
P50 | author | Bruno Pradines | Q60044507 |
P2093 | author name string | Eric Baret | |
Rémy Amalvict | |||
Hélène Savini | |||
Jérome Dormoi | |||
P2860 | cites work | Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia | Q21034146 |
Artemisinin Resistance in Plasmodium falciparum Malaria | Q22061852 | ||
Evidence of Artemisinin-Resistant Malaria in Western Cambodia | Q22061854 | ||
Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria | Q27338288 | ||
Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter | Q28375489 | ||
Synchronization of Plasmodium falciparum Erythrocytic Stages in Culture | Q29547549 | ||
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number | Q29615128 | ||
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport | Q34020238 | ||
In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene | Q34478084 | ||
Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes | Q34620579 | ||
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic | Q34648820 | ||
Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage | Q34669052 | ||
Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model | Q35753471 | ||
Role of P-glycoprotein in statin drug interactions | Q36634221 | ||
In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes | Q36757694 | ||
Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model | Q36798357 | ||
Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model | Q37152937 | ||
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study | Q37205700 | ||
Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers | Q37263344 | ||
Repeat polymorphisms in the low-complexity regions of Plasmodium falciparum ABC transporters and associations with in vitro antimalarial responses. | Q37335774 | ||
Preventing antimalarial drug resistance through combinations | Q39589995 | ||
Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas | Q39757934 | ||
Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. | Q39762005 | ||
[Antimalarial drug resistance] | Q40474269 | ||
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein | Q40789773 | ||
Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum | Q40936537 | ||
In vitro metabolism of piperaquine is primarily mediated by CYP3A4. | Q41625322 | ||
Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene | Q41935781 | ||
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria | Q41938814 | ||
Dihydroethanoanthracene derivatives reverse in vitro quinoline resistance in Plasmodium falciparum malaria | Q41940260 | ||
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin | Q41944932 | ||
Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum | Q42623845 | ||
Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin | Q42929766 | ||
Statins alone are ineffective in cerebral malaria but potentiate artesunate | Q43185216 | ||
Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin | Q43194042 | ||
Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophages | Q43264846 | ||
Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study | Q80149477 | ||
P921 | main subject | Plasmodium falciparum | Q311383 |
lumefantrine | Q904464 | ||
P304 | page(s) | 189 | |
P577 | publication date | 2014-05-25 | |
P1433 | published in | Malaria Journal | Q15749954 |
P1476 | title | In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum | |
P478 | volume | 13 |
Q100760581 | Determination of lumefantrine as an effective drug against Toxoplasma gondii infection - in vitro and in vivo study |
Q58568707 | Malaria, tuberculosis and HIV: what's new? Contribution of the Institut Hospitalo-Universitaire Méditerranée Infection in updated data |
Q56355687 | Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers |
Q27974336 | Plasmodium falciparum Werner homologue is a nuclear protein and its biochemical activities reside in the N-terminal region |
Q57167324 | Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity |
Search more.